phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Combination of Immunotherapy and Targeted Therapy Improves Survival for Patients with Advanced Colorectal Cancer

A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer, the second most common cause of cancer death in the U.S., live longer and control their disease better than with the standard treatment drug regorafenib.

October 20, 2025


October 20 2025

October 19 2025

October 18 2025

October 17 2025

October 16 2025

October 15 2025

October 14 2025

October 13 2025

October 12 2025

October 11 2025

October 10 2025

October 9 2025

October 8 2025

October 7 2025

October 6 2025

Angell Street Psychiatry
Copyright 2025 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy